Recent Updates
Recently added Catalysts
ARWR Positive Sentiment

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arrowhead Pharmaceuticals, Inc. reported its fiscal 2026 third quarter results, highlighting significant financial growth and transformational events that bolster future prospects. The company will discuss these results in a conference call scheduled for August 4, 2026. CEO Christopher Anzalone emphasized the positive developments during this period.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arrowhead Pharmaceuticals reported financial growth.
  • Transformational events support future growth.
  • Topline results announced indicate positive progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+381%
120-day peak, hindsight
Typical move
2.1%
average across 2 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
ARO-RAGE
Phase 2 · Asthma

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from

Frequently Asked Questions

When did Arrowhead report its Q3 results?

Arrowhead Pharmaceuticals reported its Q3 results on August 4, 2026.

What did the CEO say about recent events?

CEO Christopher Anzalone noted that recent events support continued growth.

What is the significance of the topline results?

The topline results indicate positive progress for Arrowhead Pharmaceuticals.

When is the conference call scheduled?

The conference call is scheduled for August 4, 2026, at 4:30 p.m. ET.

ShareAdd on Google
Tags: ARWR Viatris Investor Conferences Healthcare Arrowhead Pharmaceuticals fiscal 2026 financial results topline results
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$189M liquidity · $47M/mo burn
~1 mo
High dilution risk
Lead asset
ARO-RAGEPhase 2
Asthma →

Catalyst track record

+381%
best trade around ARWR's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ARWR.

See every catalyst's timing & PoA →